Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
FENC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.23
vs -0.14
Q2.23
N/A
-0.21
vs -0.19
Q3.23
N/A
-0.07
vs -0.31
Q4.23
N/A
-0.10
vs -0.26
Q1.24
+304%
0.47
vs -0.23
Q2.24
N/A
-0.20
vs -0.21
Q3.24
N/A
-0.21
vs -0.07
Q4.24
N/A
-0.06
vs -0.10
Q1.25
N/A
-0.09
vs 0.47
Q2.25
N/A
-0.07
vs -0.20
Sales Growth
YoY
Current
Estimates
Q1.23
NA
1.7M vs NA
Q2.23
NA
3.3M vs NA
Q3.23
NA
6.5M vs NA
Q4.23
+534%
9.7M vs 1.5M
Q1.24
+1413%
25.4M vs 1.7M
Q2.24
+118%
7.3M vs 3.3M
Q3.24
+7%
7M vs 6.5M
Q4.24
-19%
7.9M vs 9.7M
Q1.25
-68%
8.1M vs 25.4M
Q2.25
+32%
9.6M vs 7.3M
Return on Equity
QoQ
Q1.23
+82%
0.82
vs 3.03
Q2.23
+56%
0.56
vs 0.82
Q3.23
+18%
0.18
vs 0.56
Q4.23
+23%
0.23
vs 0.18
Q1.24
+426%
4.26
vs 0.23
Q2.24
+409%
4.09
vs 4.26
Q3.24
+111%
1.11
vs 4.09
Q4.24
+29%
0.29
vs 1.11
Institutionnal Ownership
QoQ
Q1.23
58
58
vs 47
23%
Q2.23
60
60
vs 58
3%
Q3.23
59
59
vs 60
-2%
Q4.23
58
58
vs 59
-2%
Q1.24
67
67
vs 58
16%
Q2.24
62
62
vs 67
-7%
Q3.24
62
62
vs 62
NA
Q4.24
64
64
vs 62
3%
globenewswire.com
6 hours ago
globenewswire.com
7 hours ago
zacks.com
8 hours ago
seekingalpha.com
10 hours ago
globenewswire.com
16 hours ago
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
NASDAQ
Unprofitable
Unprofitable
-0.06Â ( -1.05%)
Relative Strenght
22
Volume Buzz
-77%
Earning Acce
No
Dist 52w H.
44%Relative Strength
FENC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
518%2025-Revenue
219%2025-EPS
-1524%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Cantor Fitzgerald
upgradePrevious: Not converted
2022-11-22
Now: Overweight
JonesTrading
initialisePrevious: Not converted
2022-09-07
Now: Buy
Oppenheimer
initialisePrevious: Not converted
2022-09-07
Now: Outperform
Morgan Stanley
initialisePrevious: Not converted
2022-09-07
Now: Equal-Weight
Quote Panel
Key Metrics